This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hennessy, B. T. Articles by Mills, G. B. Search for Related Content PubMed PubMed Citation Articles by Hennessy, B. T. Articles by Mills, G. B.

Pharmacodynamic Markers of Perifosine Efficacy

Authors' Affiliations: Departments of ¹ Systems Biology, ² Gynecologic Medical Oncology, ³ Experimental Diagnostic Imaging, and ⁴ Diagnostic Radiology, University of Texas M. D. Anderson Cancer Center, Houston, Texas and ⁵ Keryx Pharmaceuticals, New York, New York

Requests for reprints: Bryan T. Hennessy, CPB6.3444, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-7960; Fax: 713-745-1541; E-mail: bhennessy{at}mdanderson.org.

Purpose: It is critical to develop methods to quantify the early pharmacodynamic effects of targeted therapeutics in vivo to make drug development more efficient and ensure biologically relevant dosing. Furthermore, an ability to identify patients likely to respond to targeted therapeutics would decrease the size, duration, and cost of clinical trials, resulting in more efficient translation to improved patient outcomes. Recent studies suggest that perifosine inhibits the phosphatidylinositol-3'-kinase (PI3K) pathway by preventing cell membrane recruitment of the AKT pleckstrin homology domain.

Experimental Design: A novel functional proteomics technology, reverse phase protein array, was used to establish and quantify pharmacodynamic markers of perifosine efficacy.

Results: Perifosine selectively prevents AKT recruitment to the membrane and blocks activation of downstream effectors. Perifosine inhibited breast, ovarian, and prostate cancer models. Growth inhibition was associated with apoptosis. Activation of AKT as a consequence of genomic aberrations predicted perifosine efficacy. In cell lines and xenografts, there was a highly statistically significant correlation between the degree of antitumor efficacy of different perifosine doses and quantified down-regulation of phosphorylation of AKT and of its downstream targets, particularly S6.

Conclusions: Because of a strong correlation between proportional modulation of PI3K pathway biomarkers and quantified perifosine efficacy, it is likely that early measurement of such pharmacodynamic biomarkers with reverse phase protein array will optimize selection of responding patients and guide perifosine dosing. Furthermore, PI3K pathway activation status may allow baseline selection of patients most likely to respond to perifosine alone or in combination with other therapies.

This article has been cited by other articles:

				R. L. Dillon, R. Marcotte, B. T. Hennessy, J. R. Woodgett, G. B. Mills, and W. J. Muller Akt1 and Akt2 Play Distinct Roles in the Initiation and Metastatic Phases of Mammary Tumor Progression Cancer Res., June 15, 2009; 69(12): 5057 - 5064. [Abstract] [Full Text] [PDF]

				E. S. Neeley, S. M. Kornblau, K. R. Coombes, and K. A. Baggerly Variable slope normalization of reverse phase protein arrays Bioinformatics, June 1, 2009; 25(11): 1384 - 1389. [Abstract] [Full Text] [PDF]

				R. Agarwal, A.-M. Gonzalez-Angulo, S. Myhre, M. Carey, J.-S. Lee, J. Overgaard, J. Alsner, K. Stemke-Hale, A. Lluch, R. M. Neve, et al. Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer Clin. Cancer Res., June 1, 2009; 15(11): 3654 - 3662. [Abstract] [Full Text] [PDF]

				M. Niedermeier, B. T. Hennessy, Z. A. Knight, M. Henneberg, J. Hu, A. V. Kurtova, W. G. Wierda, M. J. Keating, K. M. Shokat, and J. A. Burger Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach Blood, May 28, 2009; 113(22): 5549 - 5557. [Abstract] [Full Text] [PDF]

				B. T. Hennessy, A.-M. Gonzalez-Angulo, K. Stemke-Hale, M. Z. Gilcrease, S. Krishnamurthy, J.-S. Lee, J. Fridlyand, A. Sahin, R. Agarwal, C. Joy, et al. Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics Cancer Res., May 15, 2009; 69(10): 4116 - 4124. [Abstract] [Full Text] [PDF]

				Y. Chen, N. Guggisberg, M. Jorda, A. Gonzalez-Angulo, B. Hennessy, G. B. Mills, C.-K. Tan, and J. M. Slingerland Combined Src and Aromatase Inhibition Impairs Human Breast Cancer Growth In vivo and Bypass Pathways Are Activated in AZD0530-Resistant Tumors Clin. Cancer Res., May 15, 2009; 15(10): 3396 - 3405. [Abstract] [Full Text] [PDF]

				S. A. Aziz, M. Davies, E. Pick, C. Zito, L. Jilaveanu, R. L. Camp, D. L. Rimm, Y. Kluger, and H. M. Kluger Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma Clin. Cancer Res., May 1, 2009; 15(9): 3029 - 3036. [Abstract] [Full Text] [PDF]

				A. M. Gonzalez-Angulo, K. Stemke-Hale, S. L. Palla, M. Carey, R. Agarwal, F. Meric-Berstam, T. A. Traina, C. Hudis, G. N. Hortobagyi, W. L. Gerald, et al. Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer Clin. Cancer Res., April 1, 2009; 15(7): 2472 - 2478. [Abstract] [Full Text] [PDF]

				Z. S. Boyd, Q. J. Wu, C. O'Brien, J. Spoerke, H. Savage, P. J. Fielder, L. Amler, Y. Yan, and M. R. Lackner Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays Mol. Cancer Ther., December 1, 2008; 7(12): 3695 - 3706. [Abstract] [Full Text] [PDF]

				K. Stemke-Hale, A. M. Gonzalez-Angulo, A. Lluch, R. M. Neve, W.-L. Kuo, M. Davies, M. Carey, Z. Hu, Y. Guan, A. Sahin, et al. An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer Cancer Res., August 1, 2008; 68(15): 6084 - 6091. [Abstract] [Full Text] [PDF]